Abstract:Valosin-containing protein (VCP), together with several partner proteins, extracts ubiquitinated client proteins from E3 ligase complex and facilitates their degradation through ubiquitin–proteasome system. Therefore, it plays an important role in regulating protein quality control and various cellular pathways. Recent studies also identified VCP as a lineage-specific essential gene in ovarian cancer. An orally bioavailable VCP inhibitor, CB-5083, is currently in Phase I clinical trials because it shows therapeutic effects in multiple tumor xenograft models. However, the mechanism of resistance to CB-5083 is unknown. Here, we characterized molecular mechanism of resistance to CB-5083. Using incremental exposure to CB-5083, we established CB-5083-resistant ovarian cancer cells that showed five- to six-fold resistance in vitro compared with parental cells. Genomic and complementary DNA sequencing of the VCP coding region revealed a pattern of co-selected mutations: (1) missense mutations at codon 470 in one copy resulting in increased ATPase activity and (2) nonsense or frameshift mutations at codon 606 or codon 616 in another copy causing the loss of allele-specific expression. Unbiased molecular docking studies showed codon 470 as a putative binding site for CB-5083. Furthermore, the analysis of somatic mutations in cancer genomes from the Cancer Genome Atlas (TCGA) indicated that codon 616 contains hotspot mutations in VCP. Thus, identification of these mutations associated with in vitro resistance to VCP inhibitors may be useful as potential theranostic markers while screening for patients to enroll in clinical trials. VCP has emerged as a viable therapeutic target for several cancer types, and therefore targeting such hyperactive VCP mutants should aid in improving the therapeutic outcome in cancer patients.

Valosin-containing Protein Regulates the Proteasome-Mediated Degradation of DNA-PKcs in Glioma Cells.

DNA-PKcs Deficiency Inhibits Glioblastoma Cell-Derived Angiogenesis after Ionizing Radiation.

Phospho-Ser784-VCP is Required for DNA Damage Response and is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer.

Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors

Targeting Hyperactivated DNA-PKcs by KU0060648 Inhibits Glioma Progression and Enhances Temozolomide Therapy Via Suppression of AKT Signaling

Pre-B-Cell Leukemia Transcription Factor 1 Regulates Expression of Valosin-Containing Protein, a Gene Involved in Cancer Growth

Targeting Valosin-Containing Protein Enhances the Efficacy of Radiation Therapy in Esophageal Squamous Cell Carcinoma.

Correlation of DNA-PK Activity with Anti-Cancer Drug-Sensitivity in Human Gliomas

CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth

Suppression of the USP10/CCND1 Axis Induces Glioblastoma Cell Apoptosis

VPS34 Stimulation of P62 Phosphorylation for Cancer Progression

The Coordinated Action of VCP/p97 and GCN2 Regulates Cancer Cell Metabolism and Proteostasis During Nutrient Limitation.

Inhibiting Valosin-Containing Protein Suppresses Osteosarcoma Cell Metastasis Via AKT/nuclear Factor of Kappa B Signaling Pathway in Vitro.

Knockdown of the DNA-dependent Protein Kinase Catalytic Subunit Radiosensitizes Glioma-Initiating Cells by Inducing Autophagy.

Pyruvate Facilitates FACT-Mediated γH2AX Loading to Chromatin and Promotes the Radiation Resistance of Glioblastoma

Valosin‑containing Protein Promotes Metastasis of Osteosarcoma Through Autophagy Induction and Anoikis Inhibition Via the ERK/NF‑κβ/beclin‑1 Signaling Pathway

E74-like Factor 2 Regulates Valosin-Containing Protein Expression

Targeting DNA-PKcs Increased Anticancer Drug Sensitivity by Suppressing DNA Damage Repair in Osteosarcoma Cell Line MG63

SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1 mediated ubiquitin-dependent degradation of CDK4